Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.
East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor.
The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.
Related Articles

China Securities Co., Ltd.: Investment Outlook for the Vaccine Industry in 2026

What reasons could potentially cause the unexpected appreciation of the US dollar next year in 2026? Pay attention to the possibility of a phase reversal in the economic rhythm in the third and fourth quarters.

"The 'Sky-high Monkey' Returns to CRO, will the 20cm Big Red Pillar sound the charge for Joinn Laboratories (06127) stock price to rebound?"
China Securities Co., Ltd.: Investment Outlook for the Vaccine Industry in 2026

What reasons could potentially cause the unexpected appreciation of the US dollar next year in 2026? Pay attention to the possibility of a phase reversal in the economic rhythm in the third and fourth quarters.

"The 'Sky-high Monkey' Returns to CRO, will the 20cm Big Red Pillar sound the charge for Joinn Laboratories (06127) stock price to rebound?"

RECOMMEND

Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025

Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025

Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025


